Ranibizumab Approved by FDA for Myopic Choroidal Neovascularization

Article

The FDA’s decision follows the EU’s decision last month to similarly expand the scope of the drug’s approval to include more specific causes of vision loss and blindness.

Ranibizumab (Lucentis/Genentech) has been approved by the US Food and Drug Administration (FDA) for the treatment of myopic choroidal neovascularization (mCNV), the drug’s maker announced today. The decision makes it the first anti-vascular endothelial growth factor (VEGF) to be approved for the treatment of the condition in the United States.

 

Ranibizumab, an injection previously approved for the treatment of wet age-related macular degeneration (wAMD) and diabetic macular edema (DME), performed well enough in clinical trials for mCNV to earn the FDA’s blessing. In the phase 3 RADIANCE trial, patients receiving ranibizumab regained 12 letters of visual acuity at three months, compared to less than two letters in a group receiving verteporfin photodynamic therapy. The study included 276 patients and two ranibizumab groups, both of which showed 12 or more letters of progress.

 

Choroidal neovascular membranes (CNVM) are new blood vessels that grow in the choroid and leak into the retina, which can lead to blindness and myopia. CNVM are commonly associated with wAMD and are typically painless, but can cause serious and irreversible vision loss.

 

Genentech’s press release cites a 2016 study published in Opthalmology claiming that mCNV impacts as many as 0.017% of adults in the United States, or about 41,000 people. The condition’s rarity lies in the fact that it really is two conditions: myopia, or nearsightedness cause by the eye being longer than it is tall, and CNVM.

 

Ranibizumab, and other anti-VEGF drugs, are thought to work by inhibiting a key protein responsible for the growth and permeability of new blood vessels. Side effects in the RADIANCE trial were reportedly consistent with those found in previous studies of the drug. The FDA’s decision follows the EU’s decision last month to similarly expand the scope of the drug’s approvals to include more specific causes of vision loss and blindness.

Related Videos
Hong-Uyen Hua, MD; Sruthi Arepalli, MD; and Peter Kaiser, MD
Kelly Nichols, OD; Laura Periman, MD; and Mile Brujic, OD
Cindy X. Cai, MD: Impact of Race, Neighborhood on Diabetic Retinopathy Care | Image Credit: Johns Hopkins University
Dimitra Skondra, MD, PhD: Protective Effect of Metformin in Geographic Atrophy| Image Credit: University of Chicago
Deepak Sambhara, MD | Image Credit: American Society of Retina Specialists
Sean Adrean, MD: Impact of Baseline VA on Aflibercept 8 mg Outcomes in DME | Image Credit: Linkedin
Mark Barakat, MD: Stable IOP Outcomes After Aflibercept 8 mg in DME | Image Credit: Retina Macula Institute of Arizona
Roger Goldberg, MD: Impact of Dual Inhibition on Hard Exudates in DME | Image Credit: Bay Area Retina Associates
Deepayan Kar, PhD, MS: A Virtual Reality Approach to Contrast Sensitivity in AMD | Image Credit: LinkedIn
Dolly Chang, MD, PhD | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.